Best Peptides for Weight Loss

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme strongly linked to obesity and metabolic dysfunction. By selectively blocking NNMT, it raises intracellular NAD+ levels and promotes fat cell shrinkage without suppressing appetite or stimulating the central nervous system. It has emerged as one of the most promising anti-obesity compounds in the peptide-adjacent research space, attracting attention for its unique non-stimulant mechanism of action.

Adipotide (FTTP — Fat-Targeted Proapoptotic Peptide) is a peptidomimetic that selectively destroys the blood vessels feeding white adipose tissue, causing targeted fat cell death through vascular disruption. Originally developed at MD Anderson Cancer Center using cancer drug delivery technology repurposed for obesity, it produced dramatic fat loss in primate studies — 11% body weight reduction in 28 days. However, it carries significant renal risks and is considered one of the more aggressive fat loss compounds in the research peptide space.

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside, also known as Acadesine) is a potent AMP-activated protein kinase (AMPK) activator that mimics the metabolic effects of endurance exercise at the cellular level. Originally developed as a cardioprotective agent for coronary bypass surgery, it gained widespread attention after a landmark 2008 study showed it improved running endurance by 44% in sedentary mice. Banned by WADA in 2011, it remains one of the most studied exercise-mimetic compounds in metabolic research.

AOD-9604 is a modified 16-amino-acid fragment of human growth hormone (corresponding to amino acids 176–191 of the hGH sequence) that retains the potent fat-metabolizing properties of growth hormone while completely lacking its growth-promoting, diabetogenic, and IGF-1-elevating effects. Developed at Monash University in Australia, it stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from full-length GH, making it one of the most targeted and well-characterized anti-obesity peptides available. The Australian Therapeutic Goods Administration (TGA) has granted it GRAS (Generally Recognized as Safe) status for food use, and it has also shown promising cartilage-regenerative properties.

BAM-15 is a next-generation mitochondrial uncoupling agent that dissipates the proton gradient across the inner mitochondrial membrane, converting stored energy directly into heat rather than ATP. Unlike the notorious uncoupler DNP (2,4-dinitrophenol), BAM-15 selectively targets mitochondrial membranes without depolarizing the plasma membrane, providing a dramatically wider therapeutic window. In preclinical studies, it reduces body fat by up to 20%, improves insulin sensitivity, and reverses fatty liver disease — all without affecting food intake or lean mass.

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk that reduces appetite and food intake by activating amylin receptors in the brainstem — a satiety pathway distinct from and complementary to GLP-1 signaling. When combined with semaglutide in the CagriSema formulation, it has produced the most potent weight loss of any pharmaceutical combination studied in Phase III trials, achieving a mean 22.7% body weight reduction. As a standalone agent, cagrilintide produces meaningful weight loss that validates amylin as a major therapeutic target in obesity.

The CagriSema blend combines cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist) in a single formulation, targeting two anatomically and mechanistically distinct satiety pathways for unprecedented weight loss efficacy. This dual-mechanism approach — brainstem amylin signaling plus hypothalamic GLP-1 signaling — produced the most potent weight loss results of any pharmaceutical combination in Phase III clinical trials, with a mean 22.7% body weight reduction at 68 weeks and nearly half of participants losing over 20% of their body weight.

L-Carnitine is a naturally occurring amino acid derivative essential for mitochondrial fatty acid transport. It shuttles long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation — making it critical for fat metabolism and cellular energy production. Injectable L-Carnitine is used for enhanced fat burning, exercise performance, and metabolic support.

Mazdutide (LY3305677/IBI362) is a novel dual GLP-1/glucagon receptor agonist developed by Eli Lilly (licensed to Innovent Biologics for China). Unlike tirzepatide (which targets GLP-1/GIP), mazdutide adds glucagon receptor agonism to enhance energy expenditure and fat oxidation alongside appetite suppression. It represents the next frontier in metabolic peptide therapeutics.

Methylene blue is a synthetic phenothiazine dye that has been repurposed as a mitochondrial enhancer and neuroprotective agent. Originally used as a medical dye and antimalarial, it functions as an alternative electron carrier in the mitochondrial electron transport chain, enhancing cellular energy production and reducing oxidative stress. It is one of the oldest synthetic drugs in medicine, with a history dating back to 1876.

O-304 is a novel small-molecule AMPK activator developed by Betagenon AB that directly activates AMPK by preventing its dephosphorylation. Unlike indirect AMPK activators, O-304 maintains AMPK in its active phosphorylated state, producing exercise-mimetic and glucose-lowering effects. It has completed Phase IIa clinical trials for type 2 diabetes with promising results.

Retatrutide (LY3437943) is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors — the first 'triagonist' in its class. In Phase II clinical trials, retatrutide produced unprecedented weight loss of up to 24.2% of body weight at 48 weeks, surpassing all existing anti-obesity medications including semaglutide and tirzepatide. It represents the cutting edge of incretin-based metabolic therapy and is currently in Phase III trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH/NASH).

Reta-Cagri Blend combines retatrutide, a triple-agonist GLP-1/GIP/glucagon receptor peptide, with cagrilintide, a long-acting amylin analog. This combination targets multiple metabolic pathways simultaneously — appetite suppression, insulin sensitization, glucagon-mediated fat oxidation, and gastric emptying regulation. The blend represents a next-generation approach to obesity pharmacotherapy, leveraging synergistic mechanisms that individually have shown dramatic weight loss in clinical trials.

Semaglutide is a GLP-1 receptor agonist that has revolutionized the treatment of type 2 diabetes and obesity. FDA-approved as Ozempic (injectable, diabetes), Wegovy (injectable, obesity), and Rybelsus (oral, diabetes), it is the most widely prescribed and clinically validated peptide for metabolic disease. Semaglutide produces unprecedented weight loss of 15–17% in clinical trials and has demonstrated cardiovascular, renal, and potentially neuroprotective benefits beyond glycemic control.

SLU-PP-332 is a small-molecule agonist of the estrogen-related receptor (ERR) family, particularly ERRα, ERRβ, and ERRγ. Dubbed an 'exercise mimetic,' it activates the same transcriptional programs induced by endurance exercise — mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber gene expression. In preclinical studies, it dramatically improved exercise endurance and fatigue resistance without physical training.

Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim. Unlike tirzepatide (GLP-1/GIP), survodutide pairs GLP-1 receptor agonism with glucagon receptor agonism, specifically targeting hepatic fat metabolism and energy expenditure. It has shown remarkable efficacy for both obesity and MASH (metabolic dysfunction-associated steatohepatitis), with Phase II data demonstrating up to 19% weight loss and dramatic liver fat reduction.

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, and dopamine) originally developed for Alzheimer's and Parkinson's disease that was repurposed for obesity treatment after clinical trials revealed dramatic weight loss as a side effect. It is one of the most potent appetite suppressants studied in clinical trials, with Phase II data showing over 10% weight loss — far exceeding other centrally-acting anti-obesity agents.

Tirzepatide is a first-in-class dual GLP-1/GIP receptor agonist that has redefined the treatment landscape for type 2 diabetes and obesity. FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (obesity, 2023), tirzepatide produces the most dramatic weight loss ever seen in a pharmaceutical — up to 22.5% in the SURMOUNT-1 trial. Its dual incretin mechanism activates both GLP-1 and GIP receptors, producing superior metabolic effects compared to GLP-1-only agonists like semaglutide. Tirzepatide has also shown groundbreaking results in obstructive sleep apnea, heart failure with preserved ejection fraction, and MASH.